The Council of Scientific and Industrial Research (CSIR) has outlined a comprehensive strategy to make healthcare affordable and self‑reliant. In a written reply to the Rajya Sabha on 30 July 2026, Union Minister Dr. Jitendra Singh highlighted how CSIR’s labs are translating research into medicines, diagnostics and genomics tools, aligning with the Atmanirbhar Bharat vision.
Key Developments (2021‑2026)
- Collaboration with industry and academia for joint R&D, technology transfer and licensing.
- Establishment of advanced NGS facilities across CSIR labs.
- Launch of the GUaRDIAN Consortium and the GenomeIndia programme for rare‑disease and population genomics.
- Indigenous production of fluorescent dyes and quenchers for COVID‑19 RT‑PCR kits, reducing import dependence.
- Development of novel ophthalmic formulation of Amphotericin B for fungal keratitis in partnership with Cipla.
- Creation of a TaqMan‑like RT‑PCR kit for simultaneous detection of Dengue, Chikungunya and Zika.
- Commercialisation of CRISPR‑based diagnostics (FELUDA) and gene‑editing therapy BIRSA‑101.
- Production of gram‑scale CRM197 carrier protein to lower vaccine costs.
Important Facts
• Over 13 new drugs/products and 80+ cheaper technologies have been developed by CSIR‑CDRI. • Indigenous fluorescent dyes cut reagent costs for COVID‑19 testing by an estimated 70 %. • The CRISPR‑based FELUDA test was licensed to Tata Sons, enabling rapid, low‑cost COVID‑19 screening. • GenomeIndia has sequenced thousands of Indian genomes, creating the IndiGen database for precision medicine. • Partnerships with firms such as Cipla, Biotech Desk, Himalaya Wellness and Serum Institute illustrate a robust technology‑transfer ecosystem.
Exam Relevance
Understanding CSIR’s role helps answer GS‑3 questions on science‑technology policy, health security and self‑reliance. The initiatives illustrate how public R&D institutions can:
- Bridge the gap between laboratory research and marketable products, a key aspect of the Atmanirbhar Bharat agenda.
- Strengthen national capability in genomics, crucial for disease surveillance, precision medicine and pandemic preparedness.
- Reduce dependence on imports for critical reagents, vaccines and diagnostics, aligning with strategic autonomy.
- Generate employment and foster start‑ups through technology licensing and differential pricing.
Way Forward
To maximise impact, CSIR should:
- Scale up manufacturing of successful technologies in public‑sector units to ensure wider accessibility.
- Enhance data sharing from GenomeIndia for policy‑driven health interventions.
- Strengthen regulatory pathways for fast‑track approval of indigenous diagnostics and therapeutics.
- Promote skill‑development programmes to create a workforce adept in genomics, bio‑informatics and advanced manufacturing.
These steps will consolidate India’s position as a self‑reliant, innovation‑driven healthcare ecosystem, directly supporting the nation’s health security and economic growth.